Author

Gargi Baluni

Observed names: Baluni, Gargi, G Baluni, G. Baluni

ORCID: 0009-0008-2484-7739

Observed ORCID: 0009-0008-2484-7739

OpenAlex ID: A5025650765

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

2022 · Raquel Aguiar-Ibáñez, Chloë Hardern, et al. · Journal of Medical Economics · 36

Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina

2021 · Victoria Wurcel, Emilie Scherrer, et al. · Oncology and Therapy · 11

Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection

2023 · Cesar Lopez-Vinueza, Juan Urrego-Reyes, et al. · Advances in Therapy · 8

Estimating the Age of Disease-causal HPV Infection Based on the Natural History of CIN2+ Among Females in Canada

2025 · A Cherif, X You, et al. · Open Forum Infectious Diseases · 1

Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study

2026 · Sabale, Ugne, Cherif, Alhaji, et al. · Figshare

Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study

2026 · Ugne Sabale, Alhaji Cherif, et al. · Human Vaccines & Immunotherapeutics

Rwd60 Age Distribution of Disease-causal Hpv Infection in Women With High-grade Cervical Intraepithelial Neoplasia in Korea

2025 · Alhaji Cherif, Xuedan You, et al. · Value in Health Regional Issues

1217P Age of disease causal human papilloma virus (HPV) infection for cervical pre-cancer in 4 European countries: A modeling study

2025 · U. Sabale, A. Cherif, et al. · Annals of Oncology

EE389 Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (CRC) from Public Payer Perspective in Brazil

2025 · Monica M. Rojas, Mariana Rosim, et al. · Value in Health

EE41 Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients With MSI-H or dMMR Unresectable or Metastatic Colorectal Cancer From Public Perspective in Mexico

2024 · D Medrano, R Acevedo, et al. · Value in Health

EE141 Cost-Effectiveness of Pembrolizumab for Adjuvant Treatment of Patients With Renal-Cell Carcinoma Who Have Undergone Nephrectomy in Colombia

2024 · J. Urrego-Reyes, Arnedo C Marrugo, et al. · Value in Health

EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data

2024 · G McCarthy, G Baluni, et al. · Value in Health

CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study

2024 · G. McCarthy, G. Baluni, et al. · Value in Health

EE671 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Renal Cell Carcinoma Post-Nephrectomy in France

2023 · M. Apert, L. Bensimon, et al. · Value in Health

Works count: 16

Citation count: 56

H-index: 3

I10-index: 2